In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models

Journal of Orthopaedic Research

Volumn 24, Issue 8, 2006, Pages 1709-1721

  Feeley, Brian T ^a   Conduah, Augustine H ^a   Sugiyama, Osamu ^a   Krenek, Lucie ^a   Chen, Irvin S Y ^a   Lieberman, Jay R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus; Bone morphogenetic protein 2 (BMP 2); Gene therapy; Lentivirus

Indexed keywords

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN 2; COMPLEMENTARY DNA; LENTIVIRUS VECTOR; LUCIFERASE; QUANTIKINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEFECT; BONE MARROW CELL; CAMERA; CONTROLLED STUDY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FRACTURE HEALING; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HINDLIMB; IN VITRO STUDY; IN VIVO STUDY; LEG MUSCLE; MOLECULAR IMAGING; MOUSE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; SCID MOUSE; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; BONE MARROW CELLS; BONE MORPHOGENETIC PROTEINS; BONE TRANSPLANTATION; CELLS, CULTURED; COLLAGEN; DISEASE MODELS, ANIMAL; GENE THERAPY; LENTIVIRUS; LUCIFERASES; MALE; MICE; MICE, SCID; OSTEOGENESIS; RADIUS FRACTURES; RATS; RATS, INBRED LEW; SURGICAL SPONGES; TRANSDUCTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES;

EID: 33747002648     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20229     Document Type: Article

References (51)

1. Boone DW. 2003. Complications of iliac crest graft and bone grafting alternatives in foot and ankle surgery. Foot Ankle Clin 8:1-14.
2. Nocini PF, Bedogni A, Valsecchi S, et al. 2003. Fractures of the iliac crest following anterior and posterior bone graft harvesting. Review of the literature and case presentation. Minerva Stomatol 52:441-448, 448-452.
3. Oakes DA, Lieberman JR. 2000. Osteoinductive applications of regional gene therapy: ex vivo gene transfer. Clin Orthop 379(suppl):S101-S112.
4. Turgeman G, Aslan H, Gazit Z, et al. 2002. Cell-mediated gene therapy for bone formation and regneration. Curr Opin Mol Ther 4:390-394.
5. Baltzer AW, Lattermann C, Whalen JD, et al. 2000. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 7:734-739.
6. Lieberman JR, Ghivizzani SC, Evans CH. 2002. Gene transfer approaches to the healing of bone and cartilage. Mol Ther 6:141-147.
7. Abe N, Lee YP, Sato M, et al. 2002. Enhancement of bone repair with a helper-dependent adenoviral transfer of bone morphogenetic protein-2. Biochem Biophys Res Commun 297:523-527.
8. Bax BE, Wozney JM, Ashhurst DE. 1999. Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia. Calcif Tissue Int 65:83-89.
9. Boden SD, Zdeblick TA, Sandhu HS, et al. 2000. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 25: 376-381.
10. Dai J, Kitagawa Y, Zhang J, et al. 2004. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64:994-999.
11. Lieberman JR, Daluiski A, Stevenson S, et al. 1999. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81:905-917.
12. Friedlaender GE, Perry CR, Cole JD, et al. 2001. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 83A(suppl. 1):S151-S158.
13. Govender S, Csimma C, Genant HK, et al. 2002. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84A:2123-2134.
14. Pecina M, Haspl M, Jelic M, et al. 2003. Repair of a resistant tibial non-union with a recombinant bone morphogenetic protein-7 (rh-BMP-7). Int Orthop 27:320-321.
15. Vaccaro AR, Patel T, Fischgrund J, et al. 2004. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine 29:1885-1892.
16. Lieberman JR, Daluiski A, Einhorn TA. 2002. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84A:1032-1044.
17. Gafni Y, Pelled G, Zilberman Y, et al. 2004. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 9:587-595.
18. Riew KD, Wright NM, Cheng S, et al. 1998. Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 63:357-360.
19. Southwood LL, Frisbie DD, Kawcak CE, et al. 2004. Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J Orthop Res 22: 66-72.
20. Zhu W, Rawlins BA, Boachie-Adjei O, et al. 2004. Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 19:2021-2032.
21. Kojaoghlanian T, Flomenberg P, Horwitz MS. 2003. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 13:155-171.
22. Poller W, Fechner H, Noutsias M, et al. 2002. Highly variable expression of virus receptors in the human cardiovascular system. Implications for cardiotropic viral infections and gene therapy. Z Kardiol 91:978-991.
23. VandenDriessche T, Collen D, Chuah MK. 2001. Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther 1:301-315.
24. Lever AM, Kaye JF, McCann E, et al. 1999. Lentivirus vectors for gene therapy. Biochem Soc Trans 27:841-847.
25. Sugiyama O, Sung An D, Kung SP, et al. 2005. Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol Ther 11:390-398.
26. Chen IY, Wu JC, Min JJ, et al. 2004. Micro-positron emission tomography imaging of cardiac gene expression in rats using bicistronic adenoviral vector-mediated gene delivery. Circulation 109:1415-1420.
27. Green LA, Yap CS, Nguyen K, et al. 2002. Indirect monitoring of endogenous gene expression by positron emission tomography (PET) imaging of reporter gene expression in transgenic mice. Mol Imaging Biol 4:71-81.
28. Iyer M, Salazar FB, Lewis X, et al. 2004. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 10:545-552.
29. Penuelas I, Mazzolini G, Boan JF, et al. 2005. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology 128:1787-1795.
30. Gharib AM, Thomasson D, Li KC. 2004. Molecular imaging of hepatocellular carcinoma. Gastroenterology 127:S153-S158.
31. Ray P, Wu AM, Gambhir SS. 2003. Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice. Cancer Res 63:1160-1165.
32. Saji H, Nakamura H, Awut I, et al. 2003. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues. Ann Thorac Cardiovasc Surg 9:295-300.
33. Wu JC, Inubushi M, Sundaresan G, et al. 2002. Optical imaging of cardiac reporter gene expression in living rats. Circulation 105:1631-1634.
34. Iris B, Zilberman Y, Zeira E, et al. 2003. Molecular imaging of the skeleton: quantitative real-time bioluminescence monitoring gene expression in bone repair and development. J Bone Miner Res 18:570-578.
35. Paroo Z, Bollinger RA, Braasch DA, et al. 2004. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 3:117-124.
36. Boden SD, Martin GJ Jr, Morone MA, et al. 1999. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine 24:1179-1185.
37. Wang JC, Kanim LE, Yoo S, et al. 2003. Effect of regional gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats. J Bone Joint Surg Am 85A:905-911.
38. Baum BJ, Goldsmith CM, Kok MR, et al. 2003. Advances in vector-mediated gene transfer. Immunol Lett 90:145-149.
39. Levasseur DN, Ryan TM, Pawlik KM, et al. 2003. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102:4312-4319.
40. Bonci D, Cittadini A, Latronico MV, et al. 2003. Advanced generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther 10:630-636.
41. Kearns-Jonker M, Fischer-Lougheed J, Shulkin I, et al. 2004. Use of lentiviral vectors to induce long-term tolerance to gal(+) heart grafts. Transplantation 77:1748-1754.
42. Deckers MM, van Bezooijen RL, van der Horst G, et al. 2002. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. Endocrinology 143:1545-1553.
43. Moutsatsos IK, Turgeman G, Zhou S, et al. 2001. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 3:449-461.
44. Peng H, Wright V, Usas A, et al. 2002. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110:751-759.
45. Dull T, Zufferey R, Kelly M, et al. 1998. A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463-8471.
46. Zufferey R, Dull T, Mandel RJ, et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873-9880.
47. Zufferey R, Nagy D, Mandel RJ, et al. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875.
48. Flaitz CM, Hicks MJ. 1998. Molecular piracy: the viral link to carcinogenesis. Oral Oncol 34:448-453.
49. Bai Y, Soda Y, Izawa K, et al. 2003. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther 10:1446-1457.
50. Koefoed M, Ito H, Gromov K, et al. 2005. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther 12:212-218.
51. Ray S, Paulmurugan R, Hildebrandt I, et al. 2004. Novel bidirectional vector strategy for amplification of therapeutic and reporter gene expression. Hum Gene Ther 15:681-690.